Skip to main content
Erschienen in: Supportive Care in Cancer 9/2011

01.09.2011 | Original Article

Paediatric oncology patient preference for oral nutritional supplements in a clinical setting

verfasst von: Jennifer Cohen, Kate Rosen, Ken K. Russell, Claire E. Wakefield, Belinda Goodenough

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Oral nutrition supplements are commonly used to increase the nutrient intake of children who are undergoing treatment for cancer. However, little research has been conducted systematically examining preferences for oral supplements in this population. This study aims to address a gap in the literature by examining taste preferences of oral nutrition supplements routinely recommended for children undergoing treatment for cancer.

Methods

Twenty-one children undergoing treatment for cancer and 38 healthy control subjects participated in an acute double-blinded feeding trial. A variety of energy drinks, available both commercially and in the hospital, were sampled. Patients rated the taste of the drinks on a 10-cm coloured analogue scale.

Results

A commercially-based drink (Moove™) rated the highest in the blinded and branded tests for the treatment (mean rating out of 10, 6.44 ± 2.69 and 7.26 ± 2.33, respectively) and control groups (mean rating, 7.61 ± 1.91 and 7.70 ± 2.32, respectively). Taste ratings were significantly higher for commercially available supplements over the hospital-prepared supplements, (p = 0.041), with no main effect for tasting condition (i.e. blinded versus branded, p = 0.902). There was a statistically significant trend such that ratings, when the brand that was known decreased for hospital supplements, while ratings for commercially available supplements increased (p = 0.014).

Conclusion

Fresh milk-based supplements were the preferred type of oral nutrition supplement in a cohort of paediatric oncology patients. The data also suggest that commercially available products are more likely to be accepted than hospital-prepared supplements. This pilot study supports the need for further research in the area of oral nutrition supplements for paediatric oncology patients as a way of determining a reliable way to estimate preferences and therefore maximise compliance. Results from this research could be also used as the basis for designing research to study the effects of flavour fatigue and long-term compliance with oral nutrition supplements in this population.
Literatur
1.
Zurück zum Zitat Mascarenhas KA, Stallings VA (1998) Nutritional assessment in pediatrics. Nutrition 14:105–115PubMedCrossRef Mascarenhas KA, Stallings VA (1998) Nutritional assessment in pediatrics. Nutrition 14:105–115PubMedCrossRef
2.
Zurück zum Zitat Holmes S (1993) Food avoidance in patients undergoing cancer chemotherapy. Support Care Cancer 1:326–330PubMedCrossRef Holmes S (1993) Food avoidance in patients undergoing cancer chemotherapy. Support Care Cancer 1:326–330PubMedCrossRef
3.
Zurück zum Zitat Sala A, Pencharz P, Barr RD (2004) Children, cancer and nutrition—a dynamic triangle in review. Cancer 100:677–687PubMedCrossRef Sala A, Pencharz P, Barr RD (2004) Children, cancer and nutrition—a dynamic triangle in review. Cancer 100:677–687PubMedCrossRef
4.
Zurück zum Zitat Wickham RS, Rehwaldt M, Kefer C et al (1994) Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 26:697–705 Wickham RS, Rehwaldt M, Kefer C et al (1994) Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 26:697–705
5.
Zurück zum Zitat Andrassy RJ, Chawals WJ (1998) Nutritional support of the pediatric oncology patient. Nutrition 14:124–129PubMedCrossRef Andrassy RJ, Chawals WJ (1998) Nutritional support of the pediatric oncology patient. Nutrition 14:124–129PubMedCrossRef
6.
Zurück zum Zitat Bowman L, Williams R, Sanders M, Ringwald-Smith K, Baker D, Gajjar A (1998) Algorithm for nutritional support: experience of the metabolic and infusion support service of St Jude Children’s Research Hospital. Int J Cancer 11:76–80CrossRef Bowman L, Williams R, Sanders M, Ringwald-Smith K, Baker D, Gajjar A (1998) Algorithm for nutritional support: experience of the metabolic and infusion support service of St Jude Children’s Research Hospital. Int J Cancer 11:76–80CrossRef
7.
Zurück zum Zitat Ladas EJ, Sacks N, Meacham L et al (2005) A multidisciplinary review of nutrition considerations in the pediatric oncology population: a perspective from the children’s oncology group. Nutr Clin Prac 20:377–393CrossRef Ladas EJ, Sacks N, Meacham L et al (2005) A multidisciplinary review of nutrition considerations in the pediatric oncology population: a perspective from the children’s oncology group. Nutr Clin Prac 20:377–393CrossRef
8.
Zurück zum Zitat Bolton J, Shannon L, Smith V et al (1990) Comparison of short-term and long-term palatability of six commercially available oral supplements. J Hum Nutr Diet 3:317–321CrossRef Bolton J, Shannon L, Smith V et al (1990) Comparison of short-term and long-term palatability of six commercially available oral supplements. J Hum Nutr Diet 3:317–321CrossRef
9.
Zurück zum Zitat Mauer AM, Burgess JB, Donaldson SS et al (1990) Special nutritional needs of children with malignancies: a review. J Ent Parent Nutr 14:315–324CrossRef Mauer AM, Burgess JB, Donaldson SS et al (1990) Special nutritional needs of children with malignancies: a review. J Ent Parent Nutr 14:315–324CrossRef
10.
Zurück zum Zitat Matsui D (2007) Assessing the palatability of medications in children. Paediatr Perinat Drug Ther 8:55–60CrossRef Matsui D (2007) Assessing the palatability of medications in children. Paediatr Perinat Drug Ther 8:55–60CrossRef
11.
Zurück zum Zitat Szoida MM, Mulder CJJ, Felt-Bersma RJF (2007) Differences in taste between two polyethylene glycol preparations. J Gastrointest Liver Dis 16:379–381 Szoida MM, Mulder CJJ, Felt-Bersma RJF (2007) Differences in taste between two polyethylene glycol preparations. J Gastrointest Liver Dis 16:379–381
12.
Zurück zum Zitat Bolton J, Abbott R, Kiely M et al (1992) Comparison of three oral sip-feed supplements in patients with cancer. J Human Nutr Diet 5:79–84CrossRef Bolton J, Abbott R, Kiely M et al (1992) Comparison of three oral sip-feed supplements in patients with cancer. J Human Nutr Diet 5:79–84CrossRef
13.
Zurück zum Zitat Parkinson SA, Lewis J, Morris R, Allbright A, Plant H, Slevin ML (1987) Oral protein and energy supplements in cancer patients. Hum Nutr: Appl Nutr 41A:233–243 Parkinson SA, Lewis J, Morris R, Allbright A, Plant H, Slevin ML (1987) Oral protein and energy supplements in cancer patients. Hum Nutr: Appl Nutr 41A:233–243
14.
Zurück zum Zitat Poustie VJ, Watling RM, Ashby D, Smyth RL (1999) Taste preferences for oral calorie supplements in children with cystic fibrosis, healthy children and healthy adults. J Human Nutr Diet 12:301–306CrossRef Poustie VJ, Watling RM, Ashby D, Smyth RL (1999) Taste preferences for oral calorie supplements in children with cystic fibrosis, healthy children and healthy adults. J Human Nutr Diet 12:301–306CrossRef
15.
Zurück zum Zitat Scalera G (2002) Effects of conditioned food aversions on nutritional behaviour in humans. Nutri Neurosci 5:159–188CrossRef Scalera G (2002) Effects of conditioned food aversions on nutritional behaviour in humans. Nutri Neurosci 5:159–188CrossRef
16.
Zurück zum Zitat Brisbois TD, Hutton JL, Baracos VE, Vi W (2006) Taste and smell abnormalities as independent cause of failure of food intake in patients with advanced cancer—an argument for the application of sensory science. J Pallative Care 22:111–128 Brisbois TD, Hutton JL, Baracos VE, Vi W (2006) Taste and smell abnormalities as independent cause of failure of food intake in patients with advanced cancer—an argument for the application of sensory science. J Pallative Care 22:111–128
17.
Zurück zum Zitat Moody K, Meyer M, Mancuso CA, Charlson M, Robbins L (2006) Exploring concerns of children with cancer. Support Care Cancer 14:960–966PubMedCrossRef Moody K, Meyer M, Mancuso CA, Charlson M, Robbins L (2006) Exploring concerns of children with cancer. Support Care Cancer 14:960–966PubMedCrossRef
18.
Zurück zum Zitat Hanigan MJ, Walter GA (1992) Nutritional support of the child with cancer. J Pediatr Oncol Nurs 9:110–118PubMedCrossRef Hanigan MJ, Walter GA (1992) Nutritional support of the child with cancer. J Pediatr Oncol Nurs 9:110–118PubMedCrossRef
19.
Zurück zum Zitat Pilner P, Salvy SJ (2006) Food neophobia in Humans. In: Shepher R, Raats M (eds) The psychology of food choice. CABI Publishing, Oxfordshire, pp 75–92CrossRef Pilner P, Salvy SJ (2006) Food neophobia in Humans. In: Shepher R, Raats M (eds) The psychology of food choice. CABI Publishing, Oxfordshire, pp 75–92CrossRef
20.
Zurück zum Zitat Skolin I, Hursti U-KK, Wahlin YB (2001) Parents’ perception of their child’s food intake after the start of chemotherapy. J Pediatr Oncol Nurs 18:124–136PubMedCrossRef Skolin I, Hursti U-KK, Wahlin YB (2001) Parents’ perception of their child’s food intake after the start of chemotherapy. J Pediatr Oncol Nurs 18:124–136PubMedCrossRef
21.
Zurück zum Zitat McGrath PA, Seifert CE, Speechley KN, Booth JC, Stitt L, Gibson MC (1996) A new analogue scale for assessing children’s pain: an initial validation study. Pain 64:435–443PubMedCrossRef McGrath PA, Seifert CE, Speechley KN, Booth JC, Stitt L, Gibson MC (1996) A new analogue scale for assessing children’s pain: an initial validation study. Pain 64:435–443PubMedCrossRef
22.
Zurück zum Zitat Williams EJ (1949) Experimental designs balanced for the estimation of residual effects of treatments. Aust J Scientific Res A2:149–168 Williams EJ (1949) Experimental designs balanced for the estimation of residual effects of treatments. Aust J Scientific Res A2:149–168
23.
Zurück zum Zitat Rahemtulla Z, Baldwin C, Spiro A et al (2005) The palatability of milk-based and non-milk based nutritional supplements in gastrointestinal cancer and the effect of chemotherapy. Clin Nutri 24:1029–1037CrossRef Rahemtulla Z, Baldwin C, Spiro A et al (2005) The palatability of milk-based and non-milk based nutritional supplements in gastrointestinal cancer and the effect of chemotherapy. Clin Nutri 24:1029–1037CrossRef
24.
Zurück zum Zitat Robinson TN, Borzekowski DLG, Matheson DM, Kraemer HC (2007) Effects of fast food branding on young children’s taste preferences. Arch Pediatr Adolesc Med 161:792–797PubMedCrossRef Robinson TN, Borzekowski DLG, Matheson DM, Kraemer HC (2007) Effects of fast food branding on young children’s taste preferences. Arch Pediatr Adolesc Med 161:792–797PubMedCrossRef
Metadaten
Titel
Paediatric oncology patient preference for oral nutritional supplements in a clinical setting
verfasst von
Jennifer Cohen
Kate Rosen
Ken K. Russell
Claire E. Wakefield
Belinda Goodenough
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2011
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0943-5

Weitere Artikel der Ausgabe 9/2011

Supportive Care in Cancer 9/2011 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.